and Mutation Status Associates with and Expression in Ovarian Cancer
Overview
Authors
Affiliations
Checkpoint molecules such as programmed cell death protein-1 (PD-1) and its ligand PD-L1 are critically required for tumor immune escape. The objective of this study was to investigate tumoral and mRNA-expression in a cohort of ovarian cancer (OC) patients in relation to tumor mutations. We analyzed mRNA expression of , and by quantitative real-time PCR in tissue of 170 patients with low grade-serous (LGSOC), high-grade serous (HGSOC), endometrioid and clear cell OC compared to 28 non-diseased tissues (ovaries and fallopian tubes) in relation to tumor protein 53 () and breast cancer gene 1/2 () mutation status. -mutated OC strongly expressed compared to wild-type OC ( = 0.028) and -mutated OC increasingly expressed ( = 0.024) and ( = 0.012) compared to wild-type OC. For the first time in human, we noted a strong correlation between tumoral and or mRNA-expression, respectively ( < 0.001). OC tissue increasingly expressed compared to healthy controls (vs. ovaries: < 0.001; vs. tubes: = 0.018). and mRNA-expression increased with higher tumor grade ( = 0.008 and = 0.027, respectively) and younger age (< median age, = 0.001). Finally, in the major subgroup of our cohort, FIGO stage III/IV HGSOC, high and mRNA-expression was associated with reduced progression-free ( = 0.024) and overall survival ( = 0.049) but only in the univariate analysis. Our study suggests that in OC / mRNA-expression is controlled by and affected by and mutations. We suggest that these mutations might serve as potential predictive factors that guide anti-/ immunotherapy.
Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers.
Moser S, Jonkers J Cancer Discov. 2025; 15(3):461-480.
PMID: 40025950 PMC: 11893084. DOI: 10.1158/2159-8290.CD-24-1326.
Li Q, Cai T, Zheng X, Zhang S, Li C, Tang H Clin Case Rep. 2025; 13(1):e70043.
PMID: 39780907 PMC: 11707256. DOI: 10.1002/ccr3.70043.
BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality.
Khalizieva A, Moser S, Bouwman P, Jonkers J Genes Dev. 2024; 39(1-2):86-108.
PMID: 39510841 PMC: 11789497. DOI: 10.1101/gad.352083.124.
Feroz B, Pan T, Leitner K, Ebner C, Steger K, Kildal W Int J Gynecol Cancer. 2024; 34(11):1711-1718.
PMID: 38969503 PMC: 11671916. DOI: 10.1136/ijgc-2023-005188.
Topalov N, Mayr D, Kuhn C, Leutbecher A, Scherer C, Kraus F Sci Rep. 2023; 13(1):22620.
PMID: 38114558 PMC: 10730610. DOI: 10.1038/s41598-023-49286-9.